Inovio Pharmaceuticals Inc (INO)

[xlt leader]

Here are some winning trades from AF... as I said he bashes small bios and loves over priced stocks.. Here is a brief history..

Do the exact opposite of what Adam says!
On November 19, 2008 Adam wrote and article slamming the company GNVC.

http://www.thestreet.com/story/10448931/1/genvec-stock-hit-by-pancreas-studys-details.html?puc=_tscrss

On November 20, 2008 I bought GNVC at .48, doing the exact opposite of what he says.

On January 23, 2010 GNVC hit 3.20........... a 667% RETURN!

I wonder what your return would be if you followed his his advice of what to buy over that same time period versus doing the exact opposite of what he says?

This guy sucks, questionable timing as the Bio Party Pooper
I have never studied law, but if a guy with no technical background can be a biotech analyst then I might as well become a lawyer. Seriously this guy is not qualified to really write about the stuff he does as if he understands it. He might have a better understanding than the average Joe, but it doesnt matter since all his stuff seems biased. I dont really think he personally financially gains from the crap he spews out, but its not impossible that someone higher up, like say the Chairman of thestreet.com or others affiliated with them might profit directly or indirectly.

If he had general calls that were negative that came out say at a time when there was no news in the stock and it was relatively tame that would be one thing, but its usually timed when a stock has really run up on some news, he comes out at that time and essentially bashes it. Its like he is the bio party pooper lol. I seldom see really good reviews from him, its mostly negative, and again timed very close to when stock have run really hard and would be vulnerable to negative news and be a good short for.

Hard for me to believe this guy is not biased somehow. I will hold him down while Cameron takes his shots haha.

Is he fit to write anything on BIOs?
Most of the companies are run by well qualified scientists and administrative personal.

Prior to commenting on anything, the guy should be either qualified or experienced on the Subject matter. Adam has neither of this traits.

In my opinion he and his boss Jim Creamer uses the Media & CNBC to AMASS wealth at the expense of ordinary Joe.

One should NOT take the opinion of such people very seriously, since they are NEITHER QUALIFIED or EXPERIENCED on the subject matter, that means they are AS IGNORANT or MORE IGNORANT THAN YOU!!

Best to ignore such unqualified people's comments and use your own Judgement and review for your advancement.

GOOD LUCK!

And Finally this article...

Posted by Posted by VFC on Jun 12, 2009

a moment of boredom I came across the latest release of 'the Street.com's Biotech Mailbag,' a biotech column where readers interact with the host, Adam Feuerstein, by sending in questions about biotech stocks which Feuerstein answers in the form of his column.

I used to follow the mailbag every week, just as I used to watch Jim Cramer's CNBC show 'Mad Money', but it didn't take me long to realize that both Cramer and Feuerstein had their own agenda- and looking out for the little guy wasn't part of it.

Cramer is great at explaining the intricacies of the market in his books, but his TV show has become a platform for lunacy and his "BUY BUY BUY" rating on a stock is usually the curse of death for that particular stock.

Likewise, Feuerstein has been dead wrong more often than not (although I haven't been keeping up with his column, so his record for being right may have improved) and he has cost the small investor big gains because of his failure to even remotely entertain an opposing view to his. He reminds me quite a bit of Keith Olbermann- someone who likes to hear himself talk, but fails to recognize that there is an opposing opinion to his.

When investing in biotech, it's best to look at both sides of the story and place your buy/sell orders accordingly. However, taking a small amount of money and, after some Due Diligence, placing it on a long shot that has a chance, as Dendreon (DNDN) did (twice), an investor has the chance at realizing substantial gains.

Feuerstein misses that point and instead of advising investors to do their own Due Diligence, he'd rather them just read his column and take his opinion as the holy grail. That's not looking out for the little guy, and I'm sure glad that I did not heed his advice when I, as a small investor just getting started in the biotech market, would have missed the boat on quite a few stocks that have realized substantial gains after he wrote them off.

What's comical about his latest column is that when asked about his constant sceptical opinions, he writes:

I do love a good bear story, I must admit. Journalists are natural-born skeptics, and the high yuck factor in biotech only exacerbates the condition.

So he's a journalist now- he says so himself.

The problem with 'journalism' today is that the so-called journalists have forgotten that it's not all about them- it's about the audience. The journalist is supposed to report the facts and the let the audience base an opinion off of those facts. An accompanying commentary isn't a bad thing, but both sides of the story need to be entertained.

Feuerstein, like NBC, doesn't get this; They think it's all about them. Rather than giving an unbiased report on a stock or news item, the likes of Feuerstein and Keith Olbermann (we'll use him as an example to represent NBC), would rather tell the audience what to think than to feed them enough information to come up with an opinion of their own.

In the investing world, an investor can ill afford this and the time spent reading a Feuerstein column would be better spent researching the market or looking for a better source of unbiased information.

Someone who reports opinion over fact, is far from a journalist, especially one that is a self-proclaimed skeptic that likes a 'good bear story'. That means that he is more likely than not to take a possibly good bull story and swing it into a bear story to suit his own satisfaction- and that can cost potential investors a lot of money.

Investors, do your own Due Diligence. That's the name of the game. Period.